Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Precision Medicine-B (02675), which increased over 9% to reach a new high of 63.75 HKD, with a trading volume of 1.04 million HKD [1] - Precision Medicine is recognized as an advanced surgical robot company in China's medical device industry, focusing on the design, development, and manufacturing of surgical robots [1] - According to Frost & Sullivan, Precision Medicine is the first company in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [1] Group 2 - Founder Securities believes that the global IPO of Precision Medicine has attracted diverse and global cornerstone investors, reigniting capital interest in the laparoscopic robot sector [1] - The current surgical penetration rate of laparoscopic surgical robots in China is less than 1%, significantly lower than the 21.9% in the United States, indicating substantial room for growth in domestic market share [1] - The market is still dominated by the Da Vinci system, which holds over 40% of the market share, suggesting that there is considerable potential for increased domestic production rates under ongoing government support and accelerated regulatory environment [1]